Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-072709
Filing Date
2025-05-15
Accepted
2025-05-15 16:27:18
Documents
45
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tcrt-20250331.htm   iXBRL 10-Q 866655
2 EX-31.1 tcrt-ex31_1.htm EX-31.1 14226
3 EX-32.1 tcrt-ex32_1.htm EX-32.1 7693
  Complete submission text file 0000950170-25-072709.txt   3971674

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20250331.xsd EX-101.SCH 793985
47 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20250331_htm.xml XML 432331
Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33038 | Film No.: 25953925
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)